600 Per Cent Multibagger Returns: Board of This Specialty Chemicals & Pharma Company Announces 10:1 Stock Split; Check Revised Record Date Inside

600 Per Cent Multibagger Returns: Board of This Specialty Chemicals & Pharma Company Announces 10:1 Stock Split; Check Revised Record Date Inside

Kiran Shroff

The stock gave multibagger returns of over 600 per cent from its 52-week low of Rs 58.20 per share.

On Friday, shares of Sudarshan Pharma Industries Ltd gained 0.62 per cent to Rs 405 per share from its previous closing of Rs 402.50 per share with an intraday high of Rs 422.60 and an intraday low of Rs 400.05. The stock’s 52-week high is Rs 452.70 per share while its 52-week low is Rs 58.20 per share.

The Board of Directors of the company approved a sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up. The company board revised the record date for the stock split from Monday, November 18, 2024, to Saturday, November 23, 2024.

Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. Operating across diverse segments, including specialty chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply, SPIL caters to a wide range of institutions and healthcare organizations. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.

DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.

Earlier, the company acquired 2,09,100 equity shares of Ishwari Healthcare Private Limited (Ishwari Healthcare), representing 51 per cent of its paid-up equity share capital, was completed. Upon completion of the acquisition, Ishwari Healthcare became a subsidiary of the Company. Ishwari Healthcare was a private limited company engaged in the business of producing, processing, preparing, treating, disinfecting, compounding, formulating, mixing, concentrating, packing, repacking, refining, adding, removing, purifying, preserving, grading, freezing, distillation, boiling, sterilizing, improving, extracting, buying, selling, reselling, trading, importing, exporting, bartering, transporting, storing, forwarding, distributing, disposing, developing, researching, discovering, manipulating, marketing, supplying, and dealing in various medical and surgical instruments, equipment, goods, products, instruments, apparatus, and devices related to all branches of medicine, surgery, and healthcare.

The company has a market cap of Rs 975 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of over 600 per cent from its 52-week low of Rs 58.20 per share. Investors should keep an eye on this micro-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice. 

Previous Article Multibagger penny stock under Rs 5 in green as company entered into a term sheet with Diponed Research International Pvt Ltd
Next Article Rs 74,595 Crore Order Book: President of India-Backed Multibagger Defence Company Bags New Order Worth Rs 500 Crore
Rate this article:
4.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR